The user has been using finasteride for five years and minoxidil foam for 1.5 years to combat hair loss, experiencing significant regrowth after an initial shedding phase with minoxidil. They shared progress pictures and discussed treatment experiences, including the addition of minoxidil to their regimen after noticing reduced efficacy with finasteride alone.
The user is happy with hair regrowth after 5 months using topical minoxidil twice daily, oral finasteride once daily, derma stamping weekly, and Watermans shampoo. They noticed darker hair and stopped using creatine, suspecting it worsened hair loss.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
A user's 5-month progress with Finasteride 1mg for hair loss, which is showing promising results; other users have suggested adding additional treatments such as Minoxidil and Derma Rolling to further boost regrowth.
A new brand is seeking 10 U.S.-based individuals aged 25+ experiencing hair loss to test a topical product containing GHK-Cu and Acetyl Tetrapeptide-3. Participants must not be using other treatments like finasteride or minoxidil and will provide feedback and photos.
KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.
FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.
GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.
The user is experiencing shedding of thick, healthy hair after using KX826 0.5% for a month. They are concerned about losing coverage and are seeking others' experiences with regrowth.
The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.
The conversation is about using oral finasteride and minoxidil for hair loss, with consideration of adding topical GHK-Cu for skin and hair benefits. The user seeks opinions on this combination.
The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.
The user has been using Minoxidil 5% since August and has noticed hair regrowth, with the left temple showing more concentrated growth and the right side having scattered single hairs. Some hairs are turning black, but the right side doesn't yet appear as full as the left.
Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.
This user has achieved impressive results after 5 months of using Finasteride and Minoxidil, which appear to have stopped hair loss and stimulated new growth. They have also incorporated derma pen treatments and supplements such as Zinc picolinate and DMAE into their regimen.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
The conversation is about a user's hair regrowth progress using topical Minoxidil 5%, a derma roller, Foligain Trioxidil shampoo, and various supplements like zinc, selenium, magnesium, B6, B7, saw palmetto, and D3 + K2. The user is seeking finasteride but faces prescription challenges in Italy.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
A 20-year-old user experienced significant hair regrowth after using 5% minoxidil foam and finasteride for four months, starting to see results after two months with no side effects. They also cut off damaged hair ends, wash their hair every other day, and advise managing stress to improve hair loss outcomes.
Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.
L'Oreal Serioxyl and Garnier Fructus Stemoxydine are compared for effectiveness in hair loss treatment. The user considers switching from Serioxyl to the cheaper Garnier Fructus but is unsure about its effectiveness and stemoxydine percentage.
A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.
User "yungnickyyp" shares 5-month progress using Fin/Min/Niz/Derm for hair loss. Others express jealousy and amazement at the significant hair regrowth.
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.
P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.